221 related articles for article (PubMed ID: 12457437)
1. Future potential of thymidylate synthase inhibitors in cancer therapy.
Lehman NL
Expert Opin Investig Drugs; 2002 Dec; 11(12):1775-87. PubMed ID: 12457437
[TBL] [Abstract][Full Text] [Related]
2. Thymidylate synthase: a target for combination therapy and determinant of chemotherapeutic response in colorectal cancer.
Van Triest B; Peters GJ
Oncology; 1999 Oct; 57(3):179-94. PubMed ID: 10545786
[TBL] [Abstract][Full Text] [Related]
3. Anticancer antifolates: current status and future directions.
McGuire JJ
Curr Pharm Des; 2003; 9(31):2593-613. PubMed ID: 14529544
[TBL] [Abstract][Full Text] [Related]
4. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase.
Banerjee D; Mayer-Kuckuk P; Capiaux G; Budak-Alpdogan T; Gorlick R; Bertino JR
Biochim Biophys Acta; 2002 Jul; 1587(2-3):164-73. PubMed ID: 12084458
[TBL] [Abstract][Full Text] [Related]
5. Folate-based thymidylate synthase inhibitors in cancer chemotherapy.
Takemura Y; Jackman AL
Anticancer Drugs; 1997 Jan; 8(1):3-16. PubMed ID: 9147608
[TBL] [Abstract][Full Text] [Related]
6. Folate-based thymidylate synthase inhibitors as anticancer drugs.
Jackman AL; Calvert AH
Ann Oncol; 1995 Nov; 6(9):871-81. PubMed ID: 8624289
[TBL] [Abstract][Full Text] [Related]
7. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
van Triest B; Pinedo HM; van Hensbergen Y; Smid K; Telleman F; Schoenmakers PS; van der Wilt CL; van Laar JA; Noordhuis P; Jansen G; Peters GJ
Clin Cancer Res; 1999 Mar; 5(3):643-54. PubMed ID: 10100718
[TBL] [Abstract][Full Text] [Related]
8. Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors.
Van Triest B; Pinedo HM; Giaccone G; Peters GJ
Ann Oncol; 2000 Apr; 11(4):385-91. PubMed ID: 10847455
[TBL] [Abstract][Full Text] [Related]
9. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.
Peters GJ; Smitskamp-Wilms E; Smid K; Pinedo HM; Jansen G
Cancer Res; 1999 Nov; 59(21):5529-35. PubMed ID: 10554030
[TBL] [Abstract][Full Text] [Related]
10. Antifolate inhibitors of thymidylate synthase as anticancer drugs.
JarmuĊa A
Mini Rev Med Chem; 2010 Nov; 10(13):1211-22. PubMed ID: 20854257
[TBL] [Abstract][Full Text] [Related]
11. A rationale for the clinical development of the thymidylate synthase inhibitor ZD9331 in ovarian and other solid tumours.
Jackman AL; Melin CJ; Kimbell R; Brunton L; Aherne GW; Theti DS; Walton M
Biochim Biophys Acta; 2002 Jul; 1587(2-3):215-23. PubMed ID: 12084463
[TBL] [Abstract][Full Text] [Related]
12. Thymidylate synthase inhibitors as anticancer agents: from bench to bedside.
Chu E; Callender MA; Farrell MP; Schmitz JC
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S80-9. PubMed ID: 12819937
[TBL] [Abstract][Full Text] [Related]
13. Thymidylate synthase: a critical target for cancer chemotherapy.
Rose MG; Farrell MP; Schmitz JC
Clin Colorectal Cancer; 2002 Feb; 1(4):220-9. PubMed ID: 12450420
[TBL] [Abstract][Full Text] [Related]
14. Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors.
Rustum YM; Harstrick A; Cao S; Vanhoefer U; Yin MB; Wilke H; Seeber S
J Clin Oncol; 1997 Jan; 15(1):389-400. PubMed ID: 8996166
[TBL] [Abstract][Full Text] [Related]
15. Thymidylate synthase: a critical target in cancer therapy?
Rustum YM
Front Biosci; 2004 Sep; 9():2467-73. PubMed ID: 15353299
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells.
Mauritz R; Bekkenk MW; Rots MG; Pieters R; Mini E; van Zantwijk CH; Veerman AJ; Peters GJ; Jansen G
Clin Cancer Res; 1998 Oct; 4(10):2399-410. PubMed ID: 9796971
[TBL] [Abstract][Full Text] [Related]
17. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
[TBL] [Abstract][Full Text] [Related]
18. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.
Shih C; Chen VJ; Gossett LS; Gates SB; MacKellar WC; Habeck LL; Shackelford KA; Mendelsohn LG; Soose DJ; Patel VF; Andis SL; Bewley JR; Rayl EA; Moroson BA; Beardsley GP; Kohler W; Ratnam M; Schultz RM
Cancer Res; 1997 Mar; 57(6):1116-23. PubMed ID: 9067281
[TBL] [Abstract][Full Text] [Related]
19. Tomudex (ZD1694): from concept to care, a programme in rational drug discovery.
Jackman AL; Boyle FT; Harrap KR
Invest New Drugs; 1996; 14(3):305-16. PubMed ID: 8958186
[TBL] [Abstract][Full Text] [Related]
20. Future challenges in the clinical development of thymidylate synthase inhibitor compounds.
Brandt DS; Chu E
Oncol Res; 1997; 9(8):403-10. PubMed ID: 9436193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
